Grants per year
Personal profile
Research Interests
Neuromuscular Disorders: Amyotrophic Lateral Sclerosis Muscular Dystropy Peripheral Neuropathy
Certifications and Licenses
| Neuromuscular Medicine | |
| Neurology |
Training Experience
| 2004 | Residency, Univ. of Illinois Hospital |
| 2005 | Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital) |
Education/Academic qualification
MD, University of Tunis
… → 1996
Research interests
- ALS
- Amyotrophic Lateral Sclerosis
- Muscular Dystrophy
- Nervous System Diseases
- Neuromuscular Disorders
- Peripheral Neuropathy
Fingerprint Dive into the research topics where Senda Ajroud-Driss is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 3 Similar Profiles
Amyotrophic Lateral Sclerosis
Medicine & Life Sciences
Diabetes Complications
Medicine & Life Sciences
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Medicine & Life Sciences
Type 1 Diabetes Mellitus
Medicine & Life Sciences
Peripheral Nervous System Diseases
Medicine & Life Sciences
Mutation
Medicine & Life Sciences
Epidemiology
Medicine & Life Sciences
Motor Neurons
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants 1999 2022
ODM-109:Effects of Oral Levosimendan(ODM-109) on Respiratory Function in Patients with ALS:
PRA Health Sciences, Orion Group
5/31/18 → 5/31/21
Project: Research project
Consortium Member and Peripheral Neuropathy Research Registry Agreement
Foundation for Peripheral Neuropathy
1/1/18 → 12/31/19
Project: Research project
Peripheral Nervous System Diseases
Registries
Research
Neuralgia
Neurologic Examination
Research Output 1998 2019
1
Citation
(Scopus)
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
on Behalf of the PRIMA Trial Investigators and the PATH Study Group, Mar 1 2019, In : Journal of the Peripheral Nervous System. 24, 1, p. 48-55 8 p.Research output: Contribution to journal › Article
Open Access
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polyneuropathies
Intravenous Immunoglobulins
Safety
Drug-Related Side Effects and Adverse Reactions
13
Citations
(Scopus)
Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis
Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T. & Obici, L., Feb 1 2019, In : Neurodegenerative disease management. 9, 1, p. 5-23 19 p.Research output: Contribution to journal › Article
Prealbumin
Cardiomyopathies
Peripheral Nervous System Diseases
Mutant Proteins
RNA Interference
Peripheral Neuropathy Research Registry: A prospective cohort
PNRR Study Group, Mar 1 2019, In : Journal of the Peripheral Nervous System. 24, 1, p. 39-47 9 p.Research output: Contribution to journal › Article
Peripheral Nervous System Diseases
Registries
Research
Biomarkers
HIV
1
Citation
(Scopus)
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study
on behalf of the PATH study group, Mar 1 2019, In : Journal of the Peripheral Nervous System. 24, 1, p. 72-79 8 p.Research output: Contribution to journal › Article
Open Access
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polyneuropathies
Intravenous Immunoglobulins
Random Allocation
Therapeutics
Intravenous versus subcutaneous immunoglobulin – Authors' reply
PATH study group, May 1 2018, In : The Lancet Neurology. 17, 5, p. 393-394 2 p.Research output: Contribution to journal › Letter
Immunoglobulins